Stock Report

All about this stock under one free report Last Updated: 06-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Balaxi Pharmaceuticals Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: BALAXI

₹25.37

up-down-arrow ₹-0.43 (-1.67%)

As on 04-Sep-2026 15:52IST

Market cap

info icon

₹140 Cr

Revenue (TTM)

info icon

₹280 Cr

P/E Ratio

info icon

57.8

P/B Ratio

info icon

0.6

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 14.10 14.05 -5.90 -4.30 3.35
EBIT 826.48 3.44 -77.90 -49.26 -31.66
Net Profit 111.93 345.70 -87.18 -60.55 -42.97
EPS 111.62 347.43 -87.16 31.05 -44.08
Book Value -- -- 7.48 9.99 28.26
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 3.6013.052.322.7510.36
Net Margin info 5.387.670.850.528.50
Return on equity info 3.5119.330.990.5911.68
Return on Capital info 5.7823.18--3.4813.01
Return on Assets info 2.5212.980.750.448.82
Debt to Equity (x) info ----0.090.220.22

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
--
3.48
13.01
2.31
37.46
Peer Median
--
14.90
14.72
18.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

0.99

Lower than Peers by 9.73

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
0.99
0.59
11.68
-1.29
32.17
Peer Median
10.72
12.77
11.67
14.92
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

0.75

Lower than Peers by 5.83

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
0.75
0.44
8.82
-0.96
22.09
Peer Median
6.58
7.09
7.86
9.06
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

2.32

Lower than Peers by 10.27

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
2.32
2.75
10.36
17.59
16.54
Peer Median
12.59
14.07
15.03
14.71
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

0.85

Lower than Peers by 7.91

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
0.85
0.52
8.50
-0.99
13.56
Peer Median
8.76
8.54
9.33
8.49
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
--
1.32
9.22
-0.12
14.18
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-5.90

Lower than Peers by 13.83

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
-5.90
-7.65
21.25
-28.28
20.42
Peer Median
7.93
13.04
10.27
11.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-77.90

Lower than Peers by 94.42

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
-77.90
-75.50
-28.56
-23.75
10.64
Peer Median
16.52
17.18
24.15
28.00
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-87.18

Lower than Peers by 104.42

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
-87.18
-94.35
1,150.28
-105.19
-3.56
Peer Median
17.25
24.83
30.29
36.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-87.16

Lower than Peers by 97.48

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
-87.16
-37.33
473.78
-113.19
5.48
Peer Median
10.32
17.80
24.50
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
--
7.48
17.28
14.49
52.51
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.09

Higher than Peers by 0.05

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
0.09
0.22
0.22
0.09
0.07
Peer Median
0.04
0.21
0.23
0.20
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
--
0.13
0.13
0.09
0.06
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

4.05

Higher than Peers by 2.31

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
4.05
4.05
4.45
3.88
3.64
Peer Median
1.74
1.83
1.79
1.96
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

2.70

Higher than Peers by 1.52

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
2.70
2.70
3.01
2.36
1.67
Peer Median
1.18
1.20
1.47
1.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

2.78

Lower than Peers by 4.97

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
2.78
2.07
8.15
1.73
42.34
Peer Median
7.76
8.17
9.42
8.58
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

48.59

Higher than Peers by 22.84

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
48.59
50.38
37.87
23.09
15.54
Peer Median
25.75
25.14
25.82
26.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.87

Higher than Peers by 0.21

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
0.87
0.83
1.03
0.97
1.62
Peer Median
0.66
0.73
0.75
0.77
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
--
166.78
103.86
81.67
43.31
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
--
109.40
100.21
141.58
110.51
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
--
45.22
49.80
90.14
75.41
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
--
230.96
154.28
133.11
78.42
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

57.78

Higher than Peers by 12.81

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
57.78
4.99
12.75
--
2.09
Peer Median
44.97
43.99
39.70
33.48
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

0.56

Lower than Peers by 3.98

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
0.56
0.35
1.52
2.74
3.13
Peer Median
4.54
4.66
3.72
4.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
--
--
--
--
--
Peer Median
0.10
0.10
0.16
0.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

14.33

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
14.33
10.30
10.56
10.98
8.72
Peer Median
--
29.36
30.23
29.90
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

140

Lower than Peers by 7,658

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Balaxi Pharmaceuticals
140
87
353
540
540
Peer Median
7,798
5,258
4,851
2,099
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...